CSPC PHARMA (01093) continued to increase research and development expenses in the first three quarters, achieving a total revenue of approximately 22.686 billion yuan.

CSPC PHARMA (01093) announced its performance for the first three quarters of 2024, with total revenue of approximately 22.686 billion yuan, net profit attributable to shareholders of approximately 3.999 billion yuan, and reported net profit attributable to shareholders of approximately 3.778 billion yuan. In addition, research and development expenses for this period increased by 5.5% compared to the same period last year, reaching 3.88 billion yuan, accounting for about 20.8% of the revenue from the pharmaceutical business. Currently, more than 60 key investigational drugs have entered the clinical or application stage, with 6 already applying for market approval and 24 products (30 indications) in the registration clinical stage. Since the beginning of the year, 2 innovative drugs (with new indications), 1 biosimilar drug, and 1 special formulation have been approved for market launch in China. Additionally, 34 clinical trial approvals have been obtained for investigational drugs, and 7 generic drugs have received drug registration approvals. In North America, 3 investigational innovative drugs have received clinical trial approvals, and 1 has been granted fast-track designation. From the beginning of 2024, the group has submitted a total of 36 international PCT applications, applied for 229 patents (127 domestic and 102 foreign), and obtained 60 patent grants (31 domestic, 29 foreign). As of September 30, 2024, the group has submitted 198 international PCT applications, applied for 2,023 patents (1,311 domestic and 712 foreign), and obtained 959 patent grants (636 domestic, 323 foreign).